Results 21 to 30 of about 36,320 (224)

Platelet prostacyclin binding in coronary artery disease [PDF]

, 1986
Reduced responsiveness of platelets to prostacyclin, reported in vitro in patients with coronary artery disease, has been thought to be a factor predisposing toward coronary thrombosis and vasospasm as a result of enhanced in vivo release of cyclic ...
Jaschonek, Karl, Weisenberger, Hans, Karsch, Karl R., Renn, Walter, Tidow, Susanne, Faul, Christoph   +5 more
core   +1 more source

Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia

Cardiology Research and Practice, 2020
Background and Objectives. Pulmonary arterial hypertension (PAH) pathomechanism involves an increased plasma level of endothelin-1 and a reduced plasma level of prostacyclin and nitric oxide.
Lucia Kris Dinarti, Anggoro Budi Hartopo, Dyah Wulan Anggrahini, Ahmad Hamim Sadewa, Budi Yuli Setianto, Abdus Samik Wahab   +5 more
doaj   +1 more source

Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function

Animals, 2022
Pulmonary hypertension (PH) is a fatal condition that affects many dogs. In humans, PH is often treated with beraprost sodium (BPS). However, the effectiveness of BPS for canine PH has not been established.
Ryohei Suzuki, Yunosuke Yuchi, Takahiro Saito, Yuyo Yasumura, Takahiro Teshima, Hirotaka Matsumoto, Hidekazu Koyama   +6 more
doaj   +1 more source

Role of prostacyclin in pulmonary hypertension. [PDF]

, 2014
Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease ...
Mackenzie, Louise; id_orcid, Ahmetaj-Shala, Blerina, Mackenzie, Louise, Mitchell, JA, Kirkby, NS, Mackenzie, LS, Mohamed, Nura, Reed, Daniel M., Reed, DM, Mohamed, Nura A., Kirkby, Nick, Ahmetaj-Shala, B, Wright, WR, Kirkby, Nicholas S., Wright, William R., MacKenzie, Louise Susan, Reed, Dan, Mohamed, N, Mitchell, Jane, Mitchell, Jane A.   +19 more
core   +1 more source

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients

Pulmonary Circulation, 2019
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or ...
Nathan Holthaus, Kurt W. Prins, Lauren Rose, Sasha Prisco, Marc Pritzker, Thenappan Thenappan   +5 more
doaj   +1 more source

Evaluation of Renal Blood Flow in Dogs during Short-Term Human-Dose Epoprostenol Administration Using Pulsed Doppler and Contrast-Enhanced Ultrasonography

Animals, 2022
Prostacyclin is an in vivo bioactive substance that regulates renal blood flow (RBF). Information regarding how epoprostenol, a prostacyclin preparation, affects RBF in dogs is lacking.
Kiwamu Hanazono, Takaharu Itami, Ikuto Hayasaka, Kenjiro Miyoshi, Ai Hori, Keiko Kato, Daiji Endoh   +6 more
doaj   +1 more source

Prostacyclin activity in portal hypertension [PDF]

, 2002
This work was performed between 1979 and 1985 when there was great interest in the role of the recently identified prostacyclin in vascular function and disorders.
Hamilton, George
core   +1 more source

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil

Pulmonary Circulation, 2023
Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat pulmonary arterial hypertension (PAH). In certain scenarios, patients may require aggressive treprostinil titration.
John F. Kingrey, Chad E. Miller, Veronica Franco, Jimmy S. Smith, Ronald Zolty, Ronald J. Oudiz, Jean M. Elwing, Jessica H. Huston, Lana Melendres‐Groves, Ashwin Ravichandran, Vijay Balasubramanian, Benjamin Wu, Stephanie Hwang, Scott Seaman, Meredith Broderick, Franck F. Rahaghi   +15 more
doaj   +1 more source

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Pulmonary Circulation, 2018
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH).
Martin Koestenberger, Georg Hansmann
doaj   +1 more source

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy

Pulmonary Circulation, 2023
Parenteral prostanoid therapy (PPT) can result in supranormal cardiac index (SCI; >4 L/min/m2) in pediatric pulmonary hypertension (PPH) patients. We evaluated the incidence, hemodynamic factors, and outcomes associated with SCI in PPH.
Kimberley G. Miles, Paul J. Critser, Patrick D. Evers, Michelle Cash, Melissa Magness, Elizabeth Geers, Meredith O'Neil, Zhiqian Gao, Nicholas J. Ollberding, Russel Hirsch   +9 more
doaj   +1 more source